Insulet is engaged in the development, manufacturing and sale of its Omnipod? System, an insulin delivery system for people with insulin-dependent diabetes, which consists of two product lines: the Omnipod Insulin Management System and Omnipod DASH? Insulin Management System. The Omnipod System features a self-adhesive disposable tubeless Pod, which is worn on the body and provides up to three days of non-stop insulin delivery without the need to see or handle a needle, and a handheld Personal Diabetes Manager. The Omnipod System communicates wirelessly, provides for automated cannula insertion and eliminates the need for multiple daily injection therapy or the use of pump and tubing.
In 2009, just as the dust was settling from the last major equity and credit market crises, we launched a boutique research firm with the intention of breaking Wall Street’s biases and broken incentives:
We sought to provide investors and company analysts with a source of information that changed all that.
Many years later, our business model remains because little has changed on Wall Street.
The integrity of Valens Research is founded in our disciplined processes and analytics. No “star” analysts. No corporate advisory relationships. No-nonsense opinions and recommendations.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.